InterDigital and Keysight will demonstrate high accuracy AI-based sensing adaptable to dynamic environments for immersive, location-based use cases ...

The stock has sprinted past $50 per share, after trading at $3 less than two years ago.

The artificial intelligence ( AI ) revolution began more than two years ago with the debut of ChatGPT in November 2022. Since then, the Nasdaq Composite is up more than 74%, while shares of Nvidia have advanced by a staggering 685%.Yet, like all revolutions, the AI revolution will have stages.

AI to reshape China's financial industry, boost IT spending by 24 per cent, or US$9.5 billion, in five years, UBS says.

Shares of W. P. Carey ( NYSE: WPC ) currently sit just below $60. That's well above its low point from the past year ( in the low $50s ) and not too far from its 52-week high in the mid-$60s. Because of that, investors might be wondering if the stock is still a buy at its current price point.

Although the artificial intelligence ( AI ) sell-off due to DeepSeek's generative AI model innovation was short-lived, a handful of stocks are still off their peaks. One of them is AI king Nvidia ( NASDAQ: NVDA ) , a company that provides the computing power necessary to train all of these AI ...

After underperforming throughout 2024, shares of CVS Health ( NYSE: CVS ) are surging. From the end of 2024 through Feb. 14, the stock climbed 46.7% higher.Shares of the healthcare conglomerate stock notched significant gains after management presented an encouraging fourth-quarter earnings ...

Last year, Warren Buffett, through his conglomerate Berkshire Hathaway ( NYSE: BRK.A ) ( NYSE: BRK.B ) was a huge net seller of stocks. The Oracle of Omaha took a hacksaw to his two largest stakes in Apple and Bank of America, selling a massive $133 billion against just $6 billion in buys through ...

Fund manager Gary Black on Monday advised Tesla Inc. TSLA investors to "limit the emotion" tied to the product and look at the stock analytically.

Pfizer ( NYSE: PFE ) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent times. Thanks to its coronavirus treatment and vaccine, the pharma giant reported more than $100 billion in revenue in 2022 at the peak of its pandemic success.